Search Result

Results for "

Target engagement

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bcl-2 Family (1) Caspase (1) CD28 (1) CDK (1) Dihydrofolate reductase (DHFR) (2) DNA/RNA Synthesis (13) Epigenetic Reader Domain (1) HDAC (1) Parasite (1) Protein Arginine Deiminase (2) RAR/RXR (1)
By Research Areas:	Cancer (21) Inflammation/Immunology (3)

Inhibitors & Agonists

Inhibitory Antibodies

Targets Recommended: Target Protein Ligand-Linker Conjugates Ligands for Target Protein for PROTAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112088

AZD4573 Maximum Cited Publications 13 Publications Verification	CDK	Cancer
AZD4573 is a potent and highly selective CDK9 inhibitor (IC₅₀ of <4 nM) that enables transient target engagement for the treatment of hematologic malignancies .

HY-136557A

AFM32a hydrochloride 1 Publications Verification PAD2-IN-1 hydrochloride	Protein Arginine Deiminase	Inflammation/Immunology Cancer
AFM32a (PAD2-IN-1) hydrochloride, a benzimidazole-based derivative, is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor. AFM32a hydrochloride shows superior selectivity for PAD2 over PAD4 (95-fold) and PAD3 (79-fold) .

HY-148281

TMX-2164	Bcl-2 Family	Cancer
TMX-2164 is a potent, irreversible B-cell lymphoma 6 (BCL6) inhibitor with an IC₅₀ value of 152 nM. TMX-2164 displays sustained target engagement and antiproliferative activity in cells .

HY-112081A

BAY-707 acetate	DNA/RNA Synthesis	Others
BAY-707 acetate is a highly potent and selective substrate-competitive inhibitor of MTH1 with superior cellular target engagement and pharmacokinetic properties.

HY-136557

AFM32a PAD2-IN-1	Protein Arginine Deiminase	Inflammation/Immunology Cancer
AFM32a (PAD2-IN-1), a benzimidazole-based derivative, is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor. AFM32a shows superior selectivity for PAD2 over PAD4 (95-fold) and PAD3 (79-fold) .

HY-157610

DHX9-IN-14	DNA/RNA Synthesis	Cancer
DHX9-IN-14 (161) is a RNA helicase DHX9 inhibitor, with an EC₅₀ of 3.4 μM in DHX9 cellular target engagement. Used in cancer research .

HY-157607

DHX9-IN-15	DNA/RNA Synthesis	Cancer
DHX9-IN-15 (287) is a RNA helicase DHX9 inhibitor, with an EC₅₀ of 0.232 μM in DHX9 cellular target engagement. Used in cancer research .

HY-157609

DHX9-IN-12	DNA/RNA Synthesis	Cancer
DHX9-IN-12 (83) is a RNA helicase DHX9 inhibitor, with an EC₅₀ of 0.917 μM in DHX9 cellular target engagement. Used in cancer research .

HY-157612

DHX9-IN-16	DNA/RNA Synthesis	Cancer
DHX9-IN-16 (208) is a RNA helicase DHX9 inhibitor, with an EC₅₀ of 0.125 μM in DHX9 cellular target engagement. Used in cancer research .

HY-157603

DHX9-IN-7	DNA/RNA Synthesis	Cancer
DHX9-IN-7 (550) is a RNA helicase DHX9 inhibitor, with an EC₅₀ of 0.105 μM in DHX9 cellular target engagement. Used in cancer research .

HY-157606

DHX9-IN-13	DNA/RNA Synthesis	Cancer
DHX9-IN-13 (389) is a RNA helicase DHX9 inhibitor, with an EC₅₀ of 3.4 μM in DHX9 cellular target engagement. Used in cancer research .

HY-157604

DHX9-IN-9	DNA/RNA Synthesis	Cancer
DHX9-IN-9 (509) is a RNA helicase DHX9 inhibitor, with an EC₅₀ of 0.0177 μM in DHX9 cellular target engagement. Used in cancer research .

HY-157605

DHX9-IN-11	DNA/RNA Synthesis	Cancer
DHX9-IN-11 (469) is a RNA helicase DHX9 inhibitor, with an EC₅₀ of 0.0838 μM in DHX9 cellular target engagement. Used in cancer research .

HY-157608

DHX9-IN-10	DNA/RNA Synthesis	Cancer
DHX9-IN-10 (49) is a RNA helicase DHX9 inhibitor, with an EC₅₀ of 9.04 μM in DHX9 cellular target engagement. Used in cancer research .

HY-157611

DHX9-IN-17	DNA/RNA Synthesis	Cancer
DHX9-IN-17 (186) is a RNA helicase DHX9 inhibitor, with an EC₅₀ of 0.161 μM in DHX9 cellular target engagement. Used in cancer research .

HY-157602

DHX9-IN-8	DNA/RNA Synthesis	Cancer
DHX9-IN-8 (Compound 6) is a RNA helicase DHX9 inhibitor, with an EC₅₀ of 3.4 μM in DHX9 cellular target engagement. Used in cancer research .

HY-111573

KCL-286	RAR/RXR	Others
Anticancer agent 168 is an orally active retinoic acid receptor (RAR/RXR) beta2 agonist with ameliorating effects on spinal cord injury (SCI) .

HY-156782

DHX9-IN-1 1 Publications Verification	DNA/RNA Synthesis	Cancer
DHX9-IN-1 (example 160) is an inhibitor of ATP-dependent RNA helicase A (DHX9), with an EC₅₀ value of 6.94 μM in DHX9 cellular target engagement. DHX9-IN-1 has antitumor activity .

HY-169922

HDAC-IN-82	HDAC Parasite Caspase	Cancer
HDAC-IN-82 (Compound 18b) is a histone deacetylase (HDAC) inhibitor with selective antiplasmodial and anticancer activity. HDAC-IN-82 shows potent antiproliferative activity and caspase 3/7 activation in cancer cells. HDAC-IN-82 causes hyperacetylation of histone H3 and α-tubulin .

HY-136521

AZ13824374	Epigenetic Reader Domain	Cancer
AZ13824374 is a highly potent and selective ATAD2 bromodomain inhibitor which shows cellular target engagement and antiproliferative activity in a range of breast cancer models. AZ13824374 inhibits ATAD2 with pIC₅₀s of 8.2 and 6.2 in ATAD2 FRET assay and ATAD2 NanoBRET assay, respectively .

HY-161064

DHFR-IN-15	Dihydrofolate reductase (DHFR)	Cancer
DHFR-IN-15 (compound 34) is a dihydrofolate reductase (DHFR) inhibitor with potential anticancer activity. DHFR-IN-15 effectively binds to DHFR in cells, reducing DHFR levels to 10 nM .

HY-161063

DHFR-IN-14	Dihydrofolate reductase (DHFR)	Cancer
DHFR-IN-14 (compound 32) is a pyrimethamine (Pyr)-type, dihydrofolate reductase (DHFR) inhibitor with potential anticancer activity .

HY-P99431

KY-1044 Alomfilimab; SAR 445256	CD28	Inflammation/Immunology Cancer
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS ^high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 ⁺ T_Eff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .

Cat. No.	Product Name	Target	Research Area

HY-P99431

KY-1044 Alomfilimab; SAR 445256	CD28	Inflammation/Immunology Cancer
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS ^high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 ⁺ T_Eff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.